Engbersen Maurits P, Aalbers Arend G J, Van't Sant-Jansen Iris, Velsing Jeroen D R, Lambregts Doenja M J, Beets-Tan Regina G H, Kok Niels F M, Lahaye Max J
Department of Radiology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands.
GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Ann Surg Oncol. 2020 Sep;27(9):3516-3524. doi: 10.1245/s10434-020-08416-7. Epub 2020 Apr 1.
The aim of this study was to determine whether the extent of peritoneal metastases (PMs) on preoperative diffusion-weighted magnetic resonance imaging (DW-MRI) can be used as a biomarker of disease-free and overall survival in patients with colorectal cancer who are considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
For this retrospective cohort study, patients with PMs considered for CRS/HIPEC who underwent DW-MRI for preoperative staging in 2016-2017 were included. The DW-MRI protocol consisted of diffusion-weighted, T2-weighted, and pre- and post-gadolinium T1-weighted imaging of the chest, abdomen, and pelvis. DW-MRI images were evaluated by two independent readers to determine the extent of PMs represented by the Peritoneal Cancer Index (MRI-PCI), as well as extraperitoneal metastases. Cox regression and Kaplan-Meier analysis was performed to determine the prognostic value of DW-MRI for overall and disease-free survival.
Seventy-eight patients were included. CRS/HIPEC was planned for 53 patients and completed in 50 patients (60.5%). Median follow-up after DW-MRI was 23 months (interquartile range 13-24). The MRI-PCI of both readers showed prognostic value for overall survival, independently of whether R1 resection was achieved (hazard ratio [HR] 1.06-1.08; p < 0.05). For the patients who received successful CRS/HIPEC, the MRI-PCI also showed independent prognostic value for disease-free survival for both readers (HR 1.09-1.10; p < 0.05).
The extent of PMs on preoperative DW-MRI is an independent predictor of overall and disease-free survival and should therefore be considered as a non-invasive prognostic biomarker.
本研究旨在确定术前扩散加权磁共振成像(DW-MRI)上的腹膜转移(PMs)范围是否可作为考虑进行细胞减灭术和热灌注腹腔化疗(CRS/HIPEC)的结直肠癌患者无病生存期和总生存期的生物标志物。
对于这项回顾性队列研究,纳入了在2016年至2017年因考虑进行CRS/HIPEC而接受DW-MRI术前分期的PMs患者。DW-MRI方案包括胸部、腹部和骨盆的扩散加权、T2加权以及钆剂注射前后的T1加权成像。由两名独立的阅片者评估DW-MRI图像,以确定由腹膜癌指数(MRI-PCI)表示的PMs范围以及腹膜外转移情况。进行Cox回归和Kaplan-Meier分析以确定DW-MRI对总生存期和无病生存期的预后价值。
纳入78例患者。计划对53例患者进行CRS/HIPEC,其中50例患者完成了该治疗(60.5%)。DW-MRI后的中位随访时间为23个月(四分位间距13 - 24个月)。两位阅片者的MRI-PCI均显示出对总生存期的预后价值,与是否实现R1切除无关(风险比[HR] 1.06 - 1.08;p < 0.05)。对于成功接受CRS/HIPEC的患者,两位阅片者的MRI-PCI对无病生存期也显示出独立的预后价值(HR 1.09 - 1.10;p < 0.05)。
术前DW-MRI上的PMs范围是总生存期和无病生存期的独立预测指标,因此应被视为一种非侵入性的预后生物标志物。